- Home
- KTOS vs VRNA Comparison
KTOS vs VRNA Comparison
Compare KTOS & VRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KTOS
- VRNA
- Stock Information
- Founded
- KTOS 1994
- VRNA 2005
- Country
- KTOS United States
- VRNA United Kingdom
- Employees
- KTOS N/A
- VRNA N/A
- Industry
- KTOS Military/Government/Technical
- VRNA Biotechnology: Pharmaceutical Preparations
- Sector
- KTOS Industrials
- VRNA Health Care
- Exchange
- KTOS Nasdaq
- VRNA Nasdaq
- Market Cap
- KTOS 4.1B
- VRNA 3.4B
- IPO Year
- KTOS 1999
- VRNA 2017
- Fundamental
- Price
- KTOS $25.29
- VRNA $67.96
- Analyst Decision
- KTOS Buy
- VRNA Strong Buy
- Analyst Count
- KTOS 11
- VRNA 7
- Target Price
- KTOS $28.40
- VRNA $57.14
- AVG Volume (30 Days)
- KTOS 2.0M
- VRNA 1.3M
- Earning Date
- KTOS 02-26-2025
- VRNA 02-27-2025
- Dividend Yield
- KTOS N/A
- VRNA N/A
- EPS Growth
- KTOS N/A
- VRNA N/A
- EPS
- KTOS 0.10
- VRNA N/A
- Revenue
- KTOS $1,127,000,000.00
- VRNA $5,624,000.00
- Revenue This Year
- KTOS $12.24
- VRNA N/A
- Revenue Next Year
- KTOS $12.20
- VRNA $571.44
- P/E Ratio
- KTOS $254.57
- VRNA N/A
- Revenue Growth
- KTOS 11.30
- VRNA 1127.95
- 52 Week Low
- KTOS $16.78
- VRNA $11.39
- 52 Week High
- KTOS $35.66
- VRNA $68.64
- Technical
- Relative Strength Index (RSI)
- KTOS 26.03
- VRNA 76.88
- Support Level
- KTOS $31.98
- VRNA $62.24
- Resistance Level
- KTOS $33.29
- VRNA $65.50
- Average True Range (ATR)
- KTOS 1.37
- VRNA 2.78
- MACD
- KTOS -1.02
- VRNA 0.22
- Stochastic Oscillator
- KTOS 1.04
- VRNA 94.86
About KTOS Kratos Defense & Security Solutions Inc.
Kratos Defense & Security Solutions Inc develops and fields transformative, affordable technology, platforms, and systems. The company has two segments; The Kratos Government Solutions (KGS) segment is comprised of an aggregation of KGS operating segments, including its microwave electronic products, space, training, and cybersecurity, C5ISR/modular systems, turbine technologies, and defense and rocket support services operating segments and The Unmanned Systems segment consists of unmanned aerial, unmanned ground, unmanned seaborne and related command, control, and communications system businesses. The company derives a majority of its revenue from the Kratos Government Solutions segment.
About VRNA Verona Pharma plc
Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma.